The clinical significance of CXCL5 in non-small cell lung cancer

Kongju Wu 1,*, Shennan Yu 2,*, Qian Liu 2, Xianguang Bai 1, Xinhua Zheng 1, Kongming Wu 2

1Medical School of Pingdingshan University, Pingdingshan, Henan, 2Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China

*These authors contributed equally to this work

Abstract: As a CXC-type chemokine, ENA78/CXCL5 is an important attractant for granulocytes by binding to its receptor CXCR2. Recent studies proved that CXCL5/CXCR2 axis plays an oncogenic role in many human cancers. However, the exact clinical significance of CXCL5 in lung cancer has not been well defined. Here, we found that the serum protein expression of CXCL5 was significantly increased in non-small cell lung cancer (NSCLC) compared with that in healthy volunteers. Immunohistochemistry staining revealed that CXCL5 protein was higher in various lung cancer tissues compared with normal tissues. Moreover, CXCL5 expression correlated with histological grade, tumor size, and TNM stage in NSCLC. Elevated CXCL5 protein abundance predicted poor overall survival in adenocarcinoma patients. Further meta-analysis demonstrated that CXCL5 mRNA expression was also positively associated with tumor stage, lymph node metastasis, and worse survival. Kaplan–Meier plot analyses indicated high CXCL5 was associated with short overall survival and progression-free survival. Together, these results indicated that CXCL5 may be a potential biomarker for NSCLC.

Keywords: non-small cell lung cancer, chemokine, CXCL5, migration, prognosis

Introduction

Lung cancer is currently one of the world’s most lethal diseases. Moreover, the incidence of lung cancer has continuously risen over the last 10 years in most countries. 1 Histologically, lung cancer is divided into two categories: small cell carcinoma (SCC) and non-small cell carcinoma (NSCLC). NSCLC consists of several subtypes, including adenocarcinoma (ADC), squamous cell lung cancer (SQC), large cell lung cancer, and other rarer types. Although the discoveries of driver-mutations, such as EGFR and ALK tyrosine kinase inhibitors, and corresponding targeted therapies have dramatically improved the prognosis of a portion of NSCLC patients, the outcome for most lung cancer patients is still unsatisfactory due to late stage diagnosis. 2 As the current staging system is imprecise for estimating prognosis of lung cancer, identification of “ready to use” molecular markers for early diagnosis, progression monitoring, and prognosis prediction is critical for precision and personal management. 3

Through autocrine and paracrine signaling, cancer cells acquire growth signals and interact with the microenvironment, those cytokines and chemokines are potential biomarkers or therapeutic targets. 4,5 In the search for putative prognostic markers for early stage NSCLC, Kwalczuk et al evaluated the mRNA level of a panel of chemokines using real-time PCR. Of 23 analyzed genes, only CXCL5 was found to statistically significantly influence both overall and disease-free survival. 6

In association with its receptor, CXCR2, CXCL5 activates PI3K/AKT, MAP kinase, and β-catenin axis plays an oncogenic role in many human cancers. However, the exact clinical significance of CXCL5 in lung cancer has not been well defined. Here, we found that the serum protein expression of CXCL5 was significantly increased in non-small cell lung cancer (NSCLC) compared with that in healthy volunteers. Immunohistochemistry staining revealed that CXCL5 protein was higher in various lung cancer tissues compared with normal tissues. Moreover, CXCL5 expression correlated with histological grade, tumor size, and TNM stage in NSCLC. Elevated CXCL5 protein abundance predicted poor overall survival in adenocarcinoma patients. Further meta-analysis demonstrated that CXCL5 mRNA expression was also positively associated with tumor stage, lymph node metastasis, and worse survival. Kaplan–Meier plot analyses indicated high CXCL5 was associated with short overall survival and progression-free survival. Together, these results indicated that CXCL5 may be a potential biomarker for NSCLC.
to intracellular signaling transduction, CXCL5 induced myeloid-derived suppressor cell accumulation in a renal cell microenvironment leading to immune invasion. CXCL5 attracted CXCR2+ neutrophils into the tumor microenvironment to promote tumor progression, mediate resistance to therapy, and regulate immunosuppression.

CXCL5 expression is regulated by oncogenes and tumor suppressors. An in vitro study demonstrated that gain of function mutant p53 activated the expression of CXCL5, whereas wild-type p53 repressed CXCL5 promoter activity, indicating a mechanistic link between mutant p53 proteins and chemokines in cell motility. FoxM1b is abundantly expressed in human NSCLC and transcriptionally induces expression of genes essential for cellular proliferation. A transgenic mouse model proved that FoxM1b increased expression of chemokine ligands CXCL5, CXCL1, and CCL3.

The clinical value of CXCL5 in diagnosis and prognosis has been investigated in several cancers. Zhu et al reported that the sensitivity and specificity of CXCL5/creatinine ratio in predicting bladder cancer was 80.4 and 61.3%, respectively. Increased CXCL5 expression in cancer tissue predicted poor survival in bladder cancer patients. Detection of CXCL5 expression in urine may be a non-invasive method for bladder cancer diagnosis. The high-CXCL5-expression group exhibited poor overall survival (OS) after curative hepatic resection and the presence of tumor-infiltrating neutrophils was associated with CXCL5 expression in tumor cells.

So far, most published studies were from single institutions with relatively small patient samples, convincing results from large data analysis are still lacking. This study investigated the protein expression of CXCL5 in tumor tissue and peripheral serum of NSCLC patients. In combination with meta-analysis and exploration of an open big database, the association of CXCL5 with clinical-pathological parameters and prognosis was evaluated.

**Material and methods**

**Human lung cancer tissue microarray (TMA)**

To evaluate the expression of CXCL5 in normal lung vs various lung tumor tissues, two commercially available human TMAs were used. LC1201 with core diameter of 1 mm was purchased from US Biomax (Rockville, MD, USA) containing 27 cases of ADCs (grade 1–3) and 27 squamous carcinomas (grade 1–3), eight papillary ADCs, eight SCCs, eight lung atypical carcinoids, eight ADCs with lepidic pattern (bronchioloalveolar carcinomas), two giant cell types, eight large cell carcinomas, 12 lung cancer metastases, six normal lung tissues from autopsy, and six normal adjacent lung tissues. HLug-Ade150Sur was purchased from Outdo Biotech containing 75 human lung ADC tissues with matched adjacent lung tissues with survival follow-up for 3–5 years.

**Immunohistochemical staining and quantification analysis**

Immunohistochemical staining was performed by Bios Biotech, Inc, with a 2-step protocol as previously described. CXCL5 antibody was purchased from Santa Cruz Biotechnology Inc. (Dallas, TX, USA) (sc-292642). For quantification, four fields at 200x magnification of each spot were selected for immunohistochemical scoring. Scores were calculated on intensity and proportion of positive tumor cells in the whole tissue stains according to the Fromowitz standard as described. The staining intensity was scored as 0 (no staining), 1 (weak staining, light yellow), 2 (moderate staining, yellow brown), and 3 (strong staining, brown). The proportions of stained tumor cells were classified as 1 (0%–25% positive cells), 2 (26%–50% positive cells), 2 (51%–75% positive cells), and 3 (76%–100% positive cells). The multiplication for intensity and proportion was utilized to represent the protein levels of CXCL5.

**ELISA**

The blood samples were collected from approximately 100 patients who were diagnosed as having ADC at various stages by April 2015 in Tongji Hospital. All patients whose blood samples were used in this research provided written informed consent, and the study protocol was approved by the ethics committee of the Tongji Hospital of Huazhong University of Science and Technology. Serum samples from patients with obvious symptoms of inflammation were excluded. The ELISA kit for ENA78 (CXCL5) was purchased from CloudClone Corp (Katy, TX, USA). Diluted samples, including standard CXCL5 content, negative control and serums, were pipetted into 96-well plates pre-coated with anti-CXCL5. All procedures including incubation, washing, and detection were performed following standard manufacturer’s protocols. After stopping the reaction, optical densities (ODs) were measured at 450 nm using a BioTek microplate reader. The intensity of this signal is directly proportional to the concentration of human CXCL5 present in the standard specimen, standard curve demonstrated the linearity R² = 0.9943.

**Meta-analysis for CXCL5 on published Gene Expression Omnibus (GEO) databases**

We carried out a comprehensive search of relevant GEO databases for mRNA expression of CXCL5 through
Expression of CXCL5 correlated with cancer progression and prognosis in lung ADC

We analyzed the expression of CXCL5 in 75 cases of lung ADC with matched normal tissue and clinical-pathological parameters. The protein abundance of CXCL5 was positively correlated with tumor tissue grade, size, and TNM stage (Figure 2A–C). However, there was no statistical difference of CXCL5 expression between tumors with or without lymph node metastasis (Figure 2D). We investigated the association between cumulative OS and clinical-pathological parameters by Cox univariate regression analysis. Patients were divided into CXCL5 high and low subgroups based on the median expression of CXCL5. Cox multivariate analysis including sex, age, grade, CXCL5 expression, lymph node, and TNM stage demonstrated that high CXCL5 expression predicted worse survival of patients with cancer progression and prognosis (Figure 3A). However, Cox multivariate analysis including sex, age, grade, CXCL5 expression, lymph node, and TNM stage demonstrated that only T1–2 vs T3–4 had statistical significance (P=0.005) (Figure 3B).

Elevated serum CXCL5 in lung ADC

Next, we examined the serum CXCL5 abundance with a commercial ELISA kit. The standard curve between CXCL5 amount and OD value demonstrated an excellent linear relationship with R² = 0.9943 (Figure 4A). Fresh serum was isolated from 20 normal samples and 48 ADC patients covering pathological stage I–IV and distinct histological grades. Of 48 ADC patients, 23 were operable, stage I–IIa, while the rest of the patients were stage IIIb–IV. The results showed that ADC patients had more than a 3-fold increase of serum CXCL5 compared to normal samples (T/Normal, P<0.0001) (Figure 4B). The serum CXCL5 was higher in patients with T3–4 tumors than those with T1–2 tumors, however the difference just missed statistical significance (P=0.056). Because of the limited sample number, we did not observe a remarkable difference of CXCL5 expression in relation to tumor grade.
Figure 1 Representative images of CXCL5 expression by immunohistochemical staining.
Notes: (A) Normal, (B) adenocarcinoma, (C) squamous carcinoma, (D) papillary cancer, (E) SCLC, (F) carcinoid, (G) bronchioloalveolar cancer, (H) giant cell carcinoma, (I) metastatic tumor, (J) quantitative score of CXCL5. Magnification 200×.
Abbreviation: SCLC, small cell lung cancer.

Meta-analysis of CXCL5 mRNA expression with clinical-pathological characteristics
Nine datasets met the selection standard and were used to perform pooled analysis to evaluate the HR of CXCL5 expression. The patients were divided into CXCL5 high and low subgroups based on the median CXCL5 mRNA value. High expression of CXCL5 correlated with short OS in NSCLC (pooled HR =1.2, 95% CI, 1.03–1.39, \(P=0.971\), and \(I^2=0.0\%\)) (Figure 5A). Subgroup analysis indicated that
The clinical significance of CXCL5

A major risk was derived from ADC, however, the $P$-value failed to reach statistical significance.

Thirteen gene expression datasets were extracted to compare the mRNA level of CXCL5 between ADC and squamous cell carcinoma. The results showed that the CXCL5 mRNA profile was dramatically higher in ADC tumors than squamous carcinomas with OR 1.24 (95% CI: 1.01–1.53) (Figure 5B). Tumor tissues were grouped into early TNM stage I–II or late stage III–IV for all NSCLC patients, CXCL5 expressions were higher in III–IV than I–II with OR 1.27 (95% CI: 1.01–1.58) (Figure 5C). Then, subgroup analysis was performed to evaluate ADC and

Figure 2 Association of CXCL5 expression with pathological parameters in adenocarcinoma by immunohistochemical staining.

Notes: (A) Grade 1 vs 3, (B) T stage 1 vs 3, (C) TNM stage I vs III, (D) lymph node positive vs negative. Left panel: representative images, right panel: quantitative score.
squamous cell carcinoma, the two major subtypes of NSCLC. The collected data demonstrated that increased CXCL5 expression was associated with advanced stage only in ADC with OR 1.39 (95% CI: 1.01–1.88) (Figure 5D), but not in SQC. Further analysis of CXCL5 with lymph node status indicated that tumor tissues with high CXCL5 expression had increased risk for lymph node metastasis (OR 1.37, 95% CI: 1.06–1.77) (Figure 5E). Similarly, subgroup analysis showed this association only existed in ADC with OR 1.43 (95% CI: 1.06–1.93) (Figure 5F). However, no association was observed between the CXCL5 expressions and tumor tissue differentiation.

**Increased CXCL5 expression predicts poor survival in NSCLC**

CXCL5 mRNA expression profiles and follow-up data from 2,437 NSCLC patients were openly accessible from kmplot.com. The Kaplan–Meier curves from Cox univariate
Regression analysis indicated that patients with higher than median mRNA level of CXCL5 had shorter OS time (HR 1.16, 95% CI 1.01–1.33, P=0.036) (Figure 6A), post-progression survival (PPS) time (HR 1.49, 95% CI 1.15–1.93, P=0.0024) (Figure 6B), and progression-free survival (PFS) (HR 1.25, 95% CI 1.03–1.52, P=0.025) (Figure 6C). Further subgroup analysis demonstrated that PFS in patients with lung ADC had marginal significance (P=0.055) (Figure 6D), all other stratifications did not reach statistical significance, such as the CXCL5 expression with OS and PPS in ADC or squamous cell carcinoma. Together, these analyses indicated that high expression of CXCL5 correlated with unfavorable prognosis in patients with NSCLC.

Discussion

Besides well-known driver genes, many factors contribute to lung cancer pathogenesis and progression. Various biomarkers have been explored for diagnosis, targeted therapy, or prognosis. CXCL5 is a member of a proangiogenic subgroup of the CXC-type chemokine family. Emerging evidence has demonstrated that CXCL5 is involved in carcinogenesis and cancer progression. Arenberg et al first reported that CXCL5 was elevated in fresh NSCLC tissues and correlated with vascular density. Emerging evidence has demonstrated that CXCL5 is involved in carcinogenesis and cancer progression. Arenberg et al first reported that CXCL5 was elevated in fresh NSCLC tissues and correlated with vascular density. In an in vivo tumor model, expression of CXCL5 promoted tumor growth. This function was blocked by neutralizing anti-CXCL5 antibodies accompanied with reduced tumor vascularity and spontaneous metastases. In human NSCLC, Cox-2-enhanced tumor growth was inhibited by neutralizing CXCL5 antibody, suggesting that CXCL5 was a key downstream target. CXCR2 expression in tumor cells was associated with smoking and poor prognosis. Analysis of gene expression profiles on CXCR2 axis in human NSCLC cell lines and lung ADCs defined a gene cluster driven by CXCL5. Targeting CXCR2 axis may benefit patients with smoking-related lung ADC. Similarly, our study showed that CXCL5 protein abundance in various types of lung cancer was 3–5-fold higher than in normal lung epithelial tissues. Specifically, CXCL5 in ADC tissue correlated with tissue differentiation status, tumor size, and TNM stage. Moreover, patients with high CXCL5 expression in ADC had short cumulative survival.

Surgical resection is still regarded as the standard therapy for early NSCLC, however, many tumors recurred in less than 5 years. In the search for circulating markers for lung cancer, Shiels et al evaluated 72 serum proteins using luminex bead-based assay and found that eleven were statistically significantly associated with lung cancer risk, including CXCL5 concentration with the OR approximately 3–6. Spaks measured peripheral concentration of CXCL1 and CXCL4 to CXCL12 with annual follow-up for 6 years. Results indicated that the average CXCL5 was 882.74 pg/mL for all 56 patients, 658.33 pg/mL for 30 patients without recurrence, and 1,213.33 pg/mL for 24 cases of local relapse or systemic cancer metastasis. This research suggested that monitoring inflammation and chemokines might identify high-risk patients for precise post-surgical management. In concurrence with this report, our result showed that serum CXCL5 was 4.5-fold higher than in healthy volunteers and positively correlated with tumor stage. Meta-analysis of 20 sets of expression database indicated that high level of CXCL5 mRNA expression increased risk of death, at the same time, the Kaplan–Meier curve demonstrated that high level of CXCL5 expression decreased OS, PPS, and PFS in NSCLC. While pooled analysis of CXCL5 mRNA expression
## Figure 5

**Forest plot of HR and OS of CXCL5.**

**Notes:** (A) Relative risk of CXCL5 mRNA expression to OS in NSCLC. OR value of CXCL5 in ADC vs SQC (B) stages III–IV vs I–II in NSCLC (C) and ADC (D), OR value of CXCL5 comparing N+ and N− patients in NSCLC (E) and ADC (F).

**Abbreviations:** HR, hazard ratio; OR, odds ratio; OS, overall survival; NSCLC, non-small cell lung cancer; ADC, adenocarcinoma; SQC, squamous cell lung cancer; N+, lymph node positive; N−, lymph node negative.
indicated positive association with lymph node metastasis, CXCL5 protein abundance in ADC did not show a statistical difference between the lymph node positive and negative subgroups. We attributed this seemingly contradictory result to the limited sample size and less precise measurement in immunohistochemical staining.

It is well-known that CXCL5 recruits neutrophils into the tumor microenvironment. To test whether neutrophil infiltration could be a surrogate marker for CXCL5, we performed a regression analysis between CXCL5 with neutrophil surface marker CD15. In several datasets, there was a statistically significant positive relationship, indicating that tumor tissues with high CXCL5 expression might host more inflammatory cells (Figure S1), supporting the previous study. However, the correlation factor was not high enough to assume that this marker could replace CXCL5.

Whole-genome and transcriptome sequencing of tumor samples identified DACH1 as being involved in NSCLC. We previously reported that expression of DACH1 was significantly decreased in human NSCLC tissues and high DACH1 was a protection factor for OS and PFS, while expression of CXCL5 was increased and predicated poor prognosis. Further
Snail expression. Inhibition of CXCL5-mediated ERK/Raf/MEK/ERK activation and Egr-1 to induce androgen-independent PC-3 and DU145 cells, CXCL5 cell migration and epithelial-to-mesenchymal transition. androgen-independent prostate cancers and responsible for oncogenic role of Snail.

blockade, proving that CXCL5–CXCR2 axis mediated the tumorigenic action of Snail was abrogated with CXCR2 concentrations in tumor homogenates. Furthermore, the genesis accompanied by increased CXCL8 and CXCL5 of NSCLC led to increased angiogenesis and invasion. GSK-3β/Snail signaling and EMT phenotype, predicting poor prognosis. It may serve as a potential therapeutic target. Serum CXCL5 and SDF-1/CXCL12 levels were significantly higher in advanced gastric cancer groups than early gastric cancer group, high-risk and normal groups. Clinical-pathological serum CXCL5 was correlated with T-stage and distant metastasis. ROC curve and logistic regression demonstrated that serum CXCL5 and SDF-1/CXCL12 showed higher diagnostic accuracy compared with carcinoembryonic antigen in predicting gastric cancer. A combination of serum CXCL5, SDF-1/CXCL12, and CEA achieved 92.8% specificity and 75.0% sensitivity to predict distant metastasis of gastric cancer. Zhang et al used a novel statistical model to test serum CXCL5 for prognosis in nasopharyngeal carcinoma patients. The serum CXCL5 cutoff point was 0.805 ng/mL. Histology, T classification, clinical classification, and local recurrence were not associated with serum CXCL5 levels. However, serum CXCL5 levels were positively associated with lymph node classification, distant metastasis, and disease progression (P<0.05). A high serum CXCL5 level predicted poor 6-year OS and PFS. Furthermore, this novel model successfully divided the patients into four risk subgroups. The C-indices were 0.751 and 0.762 for the training set and the testing set, respectively. The novel statistical C–C model combining serum CXCL5 levels and clinical classification could be helpful in predicting the prognosis of nasopharyngeal carcinoma patients. Since CXCL5 has cross-action with other pathways to promote tumor growth, interfering with CXCL5 might have a synergistic anti-tumor effect. For example, Snail promotes invasion and metastasis of NSCLC by inducing epithelial–mesenchymal transition. Overexpression of Snail in NSCLC led to increased angiogenesis accompanied by increased CXCL8 and CXCL5 concentrations in tumor homogenates. Furthermore, the tumorigenic action of Snail was abrogated with CXCR2 blockade, proving that CXCL5–CXCR2 axis mediated the oncogenic role of Snail. CXCL5 was highly expressed in androgen-independent prostate cancers and responsible for cell migration and epithelial-to-mesenchymal transition. In androgen-independent PC-3 and DU145 cells, CXCL5 increased Raf/MEK/ERK activation and Egr-1 to induce Snail expression. Inhibition of CXCL5-mediated ERK/Egr-1/Snail signaling is an attractive therapeutic target for androgen-independent prostate cancer. As CXCL5 is an important mediator of tumor-derived angiogenesis, theoretically, blockade of either CXCL5 or CXCR2 may be a critical adjunct antiangiogenic therapy against pancreatic cancer.

Conclusion
CXCL5 activated AKT, MAPK signal to promote tumor proliferation, invasion, and tumor growth. It recruits neutrophils through CXCR2 receptors and is involved in the recruitment and activation of neutrophils. Experimental evidence has proven that targeting this axis by neutralized antibody to CXCL5 or using chemical inhibitor to CXCR2 has anti-tumor effect. However, those experimental studies have not been transferred to targeted therapy. Our study found that high level of CXCL5 in the peripheral serum of ADC and protein abundance of CXCL5 in the tumor tissue correlated with aggressive characteristics and associated with poor OS. Meta-analysis supported the fact that enhanced CXCL5 mRNA expression and associated aggressive phenotypes were majorly linked to lung ADC. In summary, CXCL5 could be a potential screening and prognostic marker for lung ADC.

Acknowledgments
This study was supported by National Natural Science Foundation of China (grant no 81572608) and Wuhan Science and Technology Bureau (grant no 2017060201010170).

Author contributions
Kongju Wu and Shengnan Yu collected and analyzed the data and drafted some sections. Qian Liu participated in data collection, immunohistochemical analysis, and drafted some sections. Xianguang Bai collected data, performed some statistical analysis, and drafted some sections. Xianguang Bai collected data, performed some statistical analysis, and drafted some sections. Kongming Wu and Xinhua Zheng designed the study, evaluated results, and revised the manuscript. All authors contributed toward data analysis, drafting and revising the paper and agree to be accountable for all aspects of the work.

Disclosure
The authors report no conflicts of interest in this work.

References


Supplementary material

Figure S1 Regression analysis between CXCL5 with neutrophil surface marker CD15 in GSE31210 (A), GSE37745 (B), GSE42127 (C), and GSE8894 (D).

OncoTargets and Therapy

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: http://www.dovepress.com/oncotargets-and-therapy-journal